FDA
-
-
-
-
-
-
-
Novartis wins FDA approval for oral chronic urticaria treatment
-
-
-
-
-
-
-
Barbara Weber, M.D., Elected to ITM Supervisory Board
-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
Novartis (NVS) twice-yearly Leqvio demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
-
-
-
-
-
-
-
Novartis (NVS) Announces FDA Approval of Lutathera
-
-
-
-
-
-
-
Erasca (ERAS) Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
-
-
-
-
-
-
-
Novartis (NVS) Presents new 48-week Results from Phase III APPLY-PNH Study
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

